The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”

GÖZALAN, Ahmet Uğur; DOĞANAY, Mutlu; BULUT, Aziz; KAMA, Nuri Aydın; ÖFKELİ, Özcem; OZDEMİR, Gul Daglar

doi:10.5455/annalsmedres.2019.05.303

The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”

Aziz BULUT, (Bingol State Hospital)

Özcem ÖFKELİ, (Diyarbakir Gazi Yasargil Training and Research Hospital)

Ahmet Uğur GÖZALAN, (Ankara Numune Training and Research Hospital)

Gul Daglar OZDEMİR, (Ankara Numune Training and Research Hospital)

Mutlu DOĞANAY, (Ankara Numune Training and Research Hospital)

Nuri Aydın KAMA (Bolu Abant Izzet Baysal University)

Annals of Medical Research

1 1

Yıl: 2019 Cilt: 26 Sayı: 7 Sayfa Aralığı: 1351 - 1357 Metin Dili: İngilizce DOI: 10.5455/annalsmedres.2019.05.303 İndeks Tarihi: 07-01-2020

The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”

Öz:

Aim: The purpose of the study was to investigate the effective prognostic factors on recurrence and mortality in patients withdifferential thyroid cancer.Material and Methods: The effects of various parameters of demographic characteristics, the admission symptoms, physicalexamination, laboratory findings, pathological examination, and surgical method of 184 patients, who underwent surgery due todifferential thyroid cancer between January 1986 and December 2009 in 4th General Surgical Clinic of Ankara Numune Trainingand Research Hospital, on prognosis were examined. The information of the patients was obtained from automation system ofthe hospital and Thyroid Cancer Information and Follow-Up Form of 4th General Surgical Clinic of Ankara Numune Training andResearch Hospital.Results: The sample group consisted of 172 papillary cancer patients and 12 follicular cancer patients. The mean age of the patientswas 45.4 years (15-78). There were 159 (86.4%) female patients and 25 (13.6%) male patients. The mean follow-up period of 161(87.5%) patients, who were followed up regularly, was 73.26 months (1-231). The mean recurrence period was 77.66 months (1-150).Mortality was observed in eight (4.3%) patients during their follow-up period. The mean life expectancy of those who died was 66.87months (1-150 months).*Single variable analysis revealed that the T stage and pathologic final stage were effective on recurrence. Painful nodules andpalpable lymph nodes in the neck and the papillary histological malignant subtype variant, as well as the presence of vascular andadjacent organ invasion, multicentricity, T stage, the lymph nodes, distant metastasis, and the clinical stage during the admissionwere identified to be effective on mortality.Conclusion: The risk of recurrence is high in DTC patients with high T stage and advanced pathologic stage. The rate of survival ofthose with multicentric tumors and advanced pathologic stage is low. Therefore, it is important for patients to be followed up closelywithin a postoperative multidisciplinary context.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-48.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
3. Horner MJ, Ries LAG, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER, 2009.
4. Wu XC, Chen VW, Steele B, et al. Cancer incidence in adolescents and young adults in the United States, 1992- 1997. J Adolesc Health 2003;32:405-15.
5. Wu X, Groves FD, McLaughin CC, et al. Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control 2005;16:309-20.
6. Bleyer A, Viny A, Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist 2006;11:590-60.
7. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
8. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259-77.
9. Mazzaferri EL, Jhiang SM. Differentiated thyroid cancer long-term impact of initial therapy. Trans Am Clin Climatol Assoc 1995;106:151-70.
10. Cheung CC, Ezzat S, Freeman JL, et al. Imunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001;14:338-42.
11. Clark OH. Total thyroidectomy: the treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982;:361-70.
12. Emerick GT, Duh Q-Y, Siperstein AE, et al. Diagnosis, treatment, and outcome of follicular thyroid carcinoma. Cancer 1993;72:3287-95.
13. Pasieka JL, Thompson NW, McLeod MK, et al. The incidence of bilateral well-differantiated thyroid cancer found at completion thyroidectomy. World J Surg 1992;16:711-16.
14. Scheumann GF, Seeliger H, Musholt TJ et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996;162:677-84.
15. Chao TC, Jeng LB, Lİn JD, et al. Completion thyroidectomy for differentiated thyroid carcinoma. Otolaryngol Head ang Neck Surg 1998;118:896-9.
16. Pacini F, Elisei R, Capezzone M, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomywith no difference in low- and high-risk patients. Thyroid 2001;11:877-81.
17. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control: JMCC 2000;7:229-39.
18. Baker RR, Hyland J. Papillary carcinoma of the thyroid gland. Surg Gynaecol Obstet 1985;161:546-50.
19. Mazzaferi EL. Thyroid carcinoma: papillary and follicular. In: Mazzaferi EL, Saaman N, eds. Endocrine Tumors. Cambridge: Blackwell Scientific Publications; 1993. p. 278-333.
20. Sherman SI. Thyroid Carcinoma (Seminar). Lancet 2003;361:501-11.
21. LiVolsi VA. Unusual variants of papillary thyroid carcinoma, in Mazzaferri EL, Kreisberg RA, Bar RS, editon. Adv Endocrinol Metab. St. Louis, Mosby- Year Book, 1995;39-54.
22. Salvesen H, Njolstad PR, Akslen LA, et al. Papillary thyroid carcinoma: A multivariate analysis of prognostic factors including an evaluation of the p-TNM staging system. Eur J Surg 1992;158:583-9.
23. Crile GJ, Hazard JB. Relationship of the age of the patient to the natural history and prognosis of carcinoma of the thyroid. Ann Surg 1953;138:33-8.
24. Frankenthaler RA, Sellin RV, Cangir A, et al. Lymph node metastasis from papillary follicular thyroid carcinoma in young patients. Am J Surg 1990;160:341-3.
25. Schlumberger M, De Vathaire F, et al. Differentiated thyroid carcinoma in childhood: long term follow-up of 72 patients. J Clin Endocrinol Metab 1987;65:1088-94.
26. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system is a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surg 1993;114:1050-58.
27. Tsang RW, Brierley JD, Simpson WJ, et al. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998, 82:375-88.
28. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis is an indicator of distant metastasis and poor prognosis in patients with thyroid papillary carcinoma. Cancer 1997;80:2268-72.
29. Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993;328:553-9.
30. Mazzaferri EL, Kloos RT. Using recombinant human TSH in the management of well-differentiated thyroid cancer: current strategies and future directions. Thyroid 2000, 10:767-78.
31. Loh KC, Greenspan FS, Gee L, et al. Pathological Tumor- Node-Metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82:3553–62.
32. Passler C, Prager G, Scheuba C, et al. Application of Staging Systems for Differentiated Thyroid Carcinoma in an Endemic Goiter Region With Iodine Substitution. Annals of Surg 2003;237:227-34.

APA	BULUT A, ÖFKELİ Ö, GÖZALAN A, OZDEMİR G, DOĞANAY M, KAMA N (2019). The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. , 1351 - 1357. 10.5455/annalsmedres.2019.05.303
Chicago	BULUT Aziz,ÖFKELİ Özcem,GÖZALAN Ahmet Uğur,OZDEMİR Gul Daglar,DOĞANAY Mutlu,KAMA Nuri Aydın The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. (2019): 1351 - 1357. 10.5455/annalsmedres.2019.05.303
MLA	BULUT Aziz,ÖFKELİ Özcem,GÖZALAN Ahmet Uğur,OZDEMİR Gul Daglar,DOĞANAY Mutlu,KAMA Nuri Aydın The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. , 2019, ss.1351 - 1357. 10.5455/annalsmedres.2019.05.303
AMA	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. . 2019; 1351 - 1357. 10.5455/annalsmedres.2019.05.303
Vancouver	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. . 2019; 1351 - 1357. 10.5455/annalsmedres.2019.05.303
IEEE	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N "The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”." , ss.1351 - 1357, 2019. 10.5455/annalsmedres.2019.05.303
ISNAD	BULUT, Aziz vd. "The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”". (2019), 1351-1357. https://doi.org/10.5455/annalsmedres.2019.05.303

APA	BULUT A, ÖFKELİ Ö, GÖZALAN A, OZDEMİR G, DOĞANAY M, KAMA N (2019). The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. Annals of Medical Research, 26(7), 1351 - 1357. 10.5455/annalsmedres.2019.05.303
Chicago	BULUT Aziz,ÖFKELİ Özcem,GÖZALAN Ahmet Uğur,OZDEMİR Gul Daglar,DOĞANAY Mutlu,KAMA Nuri Aydın The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. Annals of Medical Research 26, no.7 (2019): 1351 - 1357. 10.5455/annalsmedres.2019.05.303
MLA	BULUT Aziz,ÖFKELİ Özcem,GÖZALAN Ahmet Uğur,OZDEMİR Gul Daglar,DOĞANAY Mutlu,KAMA Nuri Aydın The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. Annals of Medical Research, vol.26, no.7, 2019, ss.1351 - 1357. 10.5455/annalsmedres.2019.05.303
AMA	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. Annals of Medical Research. 2019; 26(7): 1351 - 1357. 10.5455/annalsmedres.2019.05.303
Vancouver	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”. Annals of Medical Research. 2019; 26(7): 1351 - 1357. 10.5455/annalsmedres.2019.05.303
IEEE	BULUT A,ÖFKELİ Ö,GÖZALAN A,OZDEMİR G,DOĞANAY M,KAMA N "The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”." Annals of Medical Research, 26, ss.1351 - 1357, 2019. 10.5455/annalsmedres.2019.05.303
ISNAD	BULUT, Aziz vd. "The effective factors on our early and late results, recurrence and survival in differential thyroid cancers: “An analysis of 184 patients”". Annals of Medical Research 26/7 (2019), 1351-1357. https://doi.org/10.5455/annalsmedres.2019.05.303